Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

280Bio Treats First Patient in US Trial of Small Molecule RAS Signaling Inhibitor

publication date: Dec 4, 2023

280Bio has treated the first patient with TEB-17231, a small molecule inhibitor of RAS signaling being tested in solid tumor cancers with KRAS, NRS and HRAS alterations. 280Bio, a precision oncology company located in South San Francisco, is a wholly owned subsidiary of Shanghai Yingli Pharma. In preclinical trials, TEB-17231 showed potent inhibition of tumor cell proliferation, demonstrating activity with different KRAS, NRAS and HRAS alterations, including tumors that have become resistant to KRAS G12C inhibitors. TEB-17231 is being developed in collaboration with The University of Texas MD Anderson Cancer Center. More details...

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital